Second Genome Announces Agreement with Janssen on Microbiome Drug Discovery in Ulcerative Colitis

June 5, 2013, San Bruno, CA

Second Genome, Inc. announced today that the company has entered into an agreement with Janssen Biotech, Inc. (Janssen) focused on microbiome drug discovery. With the goal of advancing novel drug targets, the agreement is focused on therapeutic mechanisms in ulcerative colitis mediated by the bacterial ecosystem living within the human gut, referred to as the microbiome. Second Genome will apply its microbiome modulation discovery platform to characterize the role of bacterial populations in ulcerative colitis.

Read More

Second Genome Sponsors American Gut Initiative to Identify Links Between Type 2 Diabetes and the Human Microbiome

January 3, 2013, San Francisco, CA

Second Genome announced today an initiative with the American Gut project to explore the connection between the human microbiome and type 2 diabetes. The cooperation will bring together American Gut's broad citizen science network for microbiome sample collection with Second Genome's efforts in identifying microbiome modulators and novel therapeutics. Second Genome has made an undisclosed donation to American Gut to subsidize specimen collection for participants with type 2 diabetes.

Read More